Long-Term Safety and Efficacy of Esketamine in Patients With Treatment-Resistant Depression: A Review of Interim Results From the SUSTAIN-3 Trial
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
3
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5